Program
emavusertib
Its studies are mostly in Hematologic Neoplasms · Leukemia, Lymphocytic, Chronic, B-Cell · Leukemia, Myeloid, Acute, led by Curis.
Furthest: phase 2, since Oct 17, 20173 company-led studies, 2 open or runningNext primary completion: Jul 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Curis | 32 open or running | phase 2since Oct 17, 2017 | Oct 17, 2017 | Jul 2027phase 2 · NCT03328078 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 17, 2017First study: phase 2 study in Hematologic NeoplasmsFirst studyNCT03328078 · 152 planned · United States, Czechia, France and more
- Feb 10, 2020Phase 2 study in Leukemia, Myeloid, AcuteNCT04278768 · 366 enrolled · United States, Czechia, France and more
- Nov 26, 2025Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07271667 · 108 planned · United States, Italy, Spain
Ahead
- Jul 2027Primary completion: phase 2 study in Hematologic NeoplasmsNCT03328078
- Nov 2027Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07271667
TargetBeta
IRAK4 →read by rule
“An orally bioavailable, reversible inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), ”NCIt, by rule
Other programs on IRAK4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| IRAK4 Inhibitor AZD2962rule | AstraZeneca | phase 1 | 1 |
| ARD-885rule | artivila-shenzhen-innovation-center-ltd | phase 1 | 1 |
| HPB-092rule | hangzhou-polymed-biopharmaceuticals-inc | phase 1 | 1 |
| SAR447971 | Sanofi | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07271667Leukemia, Lymphocytic, Chronic, B-Cell · United States, Italy, Spain | 2 | Recruiting | Nov 2027 | 108 |
| NCT04278768Leukemia, Myeloid, Acute · United States, Czechia, France and more | 2 | Suspended | Apr 1, 2026 | 366 |
| NCT03328078Hematologic Neoplasms · United States, Czechia, France and more | 2 | Recruiting | Jul 2027 | 152 |
How it is read
Names in the registry
- “Emavusertib”, 4 entries
Conditions, from the studies’ own filings
- Hematologic Neoplasms, 1 study
- Leukemia, Lymphocytic, Chronic, B-Cell, 1 study
- Leukemia, Myeloid, Acute, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.